Quarter
Charts
πŸ‡ΊπŸ‡ΈUS Markets

BIOGEN INC.

BIIB

CIK 0000875045 Β· Quarterly mode Β· latest period FY2025 (Q4) (ending 2025-12-31) Β· sourced from SEC EDGAR

At a glance Β· FY2025 (Q4)

Revenue
$2.28B
↓-7.1% -$175Mvs FY2024 (Q4)
Operating Income
$392M
↓-26.4% -$141Mvs FY2024 (Q4)
Net Income
$324M
↑+21.6% +$58Mvs FY2024 (Q4)
Gross Profit
$1.78B
↓-4.7% -$87Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot Β· latest annual filed values Β· S&P 500 calibration

Weak
42/100
  • Profitability
    55ROIC 16.0% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.68 (above 1.5 = solid)
  • Leverage
    83D/E 0.34 (under 0.5 = conservative)
  • Efficiency
    11Asset Turnover 0.34x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -7.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project BIIB's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

21%

Trailing 3-yr CAGR was 21.5%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≀ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$400.48
Total enterprise IV
$58.91B
Diluted shares
0.15B
Terminal PV
$45.14B (77% of total)
Year-5 FCF
$5.32B
YearProjected FCFDiscounted PV
+1$2.48B$2.26B
+2$3.00B$2.48B
+3$3.63B$2.73B
+4$4.40B$3.00B
+5$5.32B$3.30B
Terminal$72.70B$45.14B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target β€” and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation Β· trailing 4 quarters

how the company spent its cash
Capex (TTM)
$154M
investment in PP&E
Stock buybacks (TTM)
β€”
share count reduction
Stock-based comp (TTM)
$291M
non-cash dilution

Balance sheet Β· 2025-12-31

latest filed snapshot
Total assets
$29.44B
everything owned
Total liabilities
$11.18B
everything owed
Stockholders' equity
$18.26B
shareholder claim
Net debt
$3.37B
LT debt minus cash

Recent performance Β· 71 quarters

Revenue↓-7.1% -$175M
$2.28B
Net Income↑+20.1% +$78M
$467M
Free Cash Flow↓-35.1% -$254M
$468M
Operating Margin↓-12.0pts
24.1%

Drill down